Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vanda Pharmaceuticals Inc. (VNDA)
Price$5.43Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M | $248.2M | $227.2M | $193.1M | $165.1M | $146.0M | $109.9M | $50.2M | $33.9M | $32.7M | $31.3M | $35.7M | $4.5M |
| Gross profit | $203.1M | $187.5M | $177.8M | $230.1M | $243.1M | $224.8M | $202.7M | $172.6M | — | — | $86.5M | $48.6M | — | $32.6M | — | $32.8M | $2.6M |
| Gross margin | 93.96% | 94.31% | 92.32% | 90.45% | 90.46% | 90.59% | 89.22% | 89.38% | — | — | 78.66% | 96.84% | — | 99.61% | — | 91.90% | 57.89% |
| Research & development | $109.3M | $74.4M | $76.8M | $85.8M | $75.4M | $55.6M | $48.6M | $43.6M | $38.5M | $29.2M | $29.1M | $19.2M | $28.5M | $45.8M | $29.0M | $12.3M | $13.9M |
| Operating expenses | $367.3M | $239.4M | $206.6M | $248.1M | $226.5M | $220.9M | $204.4M | $171.4M | $182.0M | $164.6M | $150.1M | $30.1M | $55.1M | $61.9M | $42.0M | $26.9M | $40.5M |
| Operating income | −$151.2M | −$40.7M | −$14.0M | $6.3M | $42.2M | $27.2M | $22.8M | $21.7M | −$16.9M | −$18.6M | −$40.2M | $20.1M | −$21.2M | −$29.2M | −$10.7M | $8.8M | −$35.9M |
| Operating margin | −69.95% | −20.46% | −7.24% | 2.49% | 15.69% | 10.98% | 10.04% | 11.26% | −10.24% | −12.72% | −36.56% | 40.00% | −62.58% | −89.16% | −34.24% | 24.75% | −790.41% |
| EBITDA | −$143.1M | −$32.5M | −$10.9M | $9.1M | $45.0M | $30.1M | $25.7M | $24.7M | −$13.9M | −$6.7M | −$26.6M | $20.6M | −$20.8M | −$28.5M | −$10.2M | $9.2M | −$35.5M |
| EBITDA margin | −66.20% | −16.36% | −5.68% | 3.56% | 16.75% | 12.13% | 11.31% | 12.79% | −8.43% | −4.59% | −24.23% | 41.06% | −61.30% | −87.22% | −32.74% | 25.69% | −780.69% |
| Net income | −$220.5M | −$18.9M | $2.5M | $6.3M | $33.2M | $23.3M | $115.6M | $25.2M | −$15.6M | −$18.0M | −$39.9M | $20.2M | −$21.1M | −$28.6M | −$9.8M | $7.2M | −$35.9M |
| Net profit margin | −102.02% | −9.51% | 1.30% | 2.47% | 12.34% | 9.40% | 50.86% | 13.05% | −9.43% | −12.33% | −36.27% | 40.25% | −62.15% | −87.44% | −31.35% | 20.14% | −788.46% |
| Basic EPSper basic share | -$3.74 | -$0.33 | $0.04 | $0.11 | $0.60 | $0.43 | $2.17 | $0.50 | -$0.35 | -$0.41 | -$0.94 | $0.58 | -$0.69 | -$1.01 | -$0.35 | $0.26 | -$1.33 |
| Diluted EPSper diluted share | -$3.74 | -$0.33 | $0.04 | $0.11 | $0.58 | $0.42 | $2.11 | $0.48 | -$0.35 | -$0.41 | -$0.94 | $0.55 | -$0.69 | -$1.01 | -$0.35 | $0.25 | -$1.33 |
Owners
Reported shareholders
12.66%of listed shares
BlackRock, Inc.7.65M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 12.66%7.65M shares |
STATE STREET CORP | 5.82%3.52M shares |
AQR CAPITAL MANAGEMENT LLC | 5.79%3.5M shares |
RENAISSANCE TECHNOLOGIES LLC | 5.69%3.44M shares |
Polymeropoulos Mihael Hristos | ≈4.47%2.7M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.18%2.52M shares |
AIGH Capital Management LLC | 3.38%2.04M shares |
ACADIAN ASSET MANAGEMENT LLC | 3.17%1.92M shares |
DIMENSIONAL FUND ADVISORS LP | 2.86%1.73M shares |
MILLENNIUM MANAGEMENT LLC | 2.65%1.6M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.45%1.48M shares |
TWO SIGMA INVESTMENTS, LP | 2.23%1.35M shares |
MARSHALL WACE, LLP | 2.03%1.23M shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 2.01%1.21M shares |
Krensavage Asset Management, LLC | 1.95%1.18M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.87%1.13M shares |
GOLDMAN SACHS GROUP INC | 1.71%1.04M shares |
CITADEL ADVISORS LLC | 1.25%758.3K shares |
Qube Research & Technologies Ltd | 1.21%729.21K shares |
FEDERATED HERMES, INC. | 1.18%714.28K shares |
Percentages use 60.45M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 2, 2026Form 4 | Moran Kevin PatrickSVP, CFO & Treasurer | SellCommon Stock | 42.4K | $8.27 | $351.0K | 411.4K |
| Mar 2, 2026Form 4 | Wijkstrom JoakimSVP, Chief Marketing Officer | SellCommon Stock | 30.8K | $8.27 | $254.7K | 333.5K |
| Mar 2, 2026Form 4 | Williams TimothySVP & General Counsel | SellCommon Stock | 42.4K | $8.27 | $350.9K | 377.4K |
| Mar 2, 2026Form 4 | Birznieks GuntherSVP, Business Development | SellCommon Stock | 42.4K | $8.27 | $350.9K | 494.2K |
| Mar 2, 2026Form 4 | Polymeropoulos Mihael HristosPresident and CEO | SellCommon Stock | 156.2K | $8.17 | $1.28M | 2.70M |